Results 311 to 320 of about 172,684 (356)
Some of the next articles are maybe not open access.
Okuläre Graft-versus-Host-Disease
Der Ophthalmologe, 2015Ocular graft versus host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (HSCT) is predominantly an inflammatory and destructive ocular surface disease with increasing incidence. It not only leads to a reduced quality-of-life but can also impair vision and in severe cases lead to blindness. The occurrence of GVHD can lead to
T, Dietrich-Ntoukas, P, Steven
openaire +3 more sources
Nature Reviews Immunology, 2007
Allogeneic haematopoietic stem-cell transplantation (SCT) is a curative therapy for haematological malignancies and inherited disorders of blood cells, such as sickle-cell anaemia. Mature alphabeta T cells that are contained in the allografts reconstitute T-cell immunity and can eradicate malignant cells in the recipient.
openaire +2 more sources
Allogeneic haematopoietic stem-cell transplantation (SCT) is a curative therapy for haematological malignancies and inherited disorders of blood cells, such as sickle-cell anaemia. Mature alphabeta T cells that are contained in the allografts reconstitute T-cell immunity and can eradicate malignant cells in the recipient.
openaire +2 more sources
Ocular graft-versus-host disease
Current Opinion in Allergy & Clinical Immunology, 2012This review was carried out to study the frequency, and severity of ocular surface involvement at the setting of allogeneic hematopoietic stem cell transplantation and subsequent graft-versus-host disease (GVHD) and evaluate the clinical outcomes of newer treatments.Ocular involvement has been reported in 60-90% of patients with chronic GVHD.
Michelle, Hessen, Esen K, Akpek
openaire +2 more sources
Journal of the American Academy of Dermatology, 1981
Graft versus host disease (GVHD) occurs in 50% to 70% of patients receiving bone marrow transplants. It can also develop in immunosuppressed patients with malignancies who receive nonirradiated blood transfusions. Most work indicates that the primary mechanism of GVHD is cell-mediated. It is likely that humoral factors are involved as well.
openaire +2 more sources
Graft versus host disease (GVHD) occurs in 50% to 70% of patients receiving bone marrow transplants. It can also develop in immunosuppressed patients with malignancies who receive nonirradiated blood transfusions. Most work indicates that the primary mechanism of GVHD is cell-mediated. It is likely that humoral factors are involved as well.
openaire +2 more sources
Chronic Graft-Versus-Host Disease
Journal of Hematotherapy & Stem Cell Research, 2000bidity following BMT is graft-versus-host disease (GVHD). In several large recent trials, 40‐ 60% of patients surviving more than 100 days have developed chronic GVHD (1‐ 3). The incidence of chronic GVHD is expected to rise due to several trends in transplantation.
J, Margolis, G, Vogelsang
openaire +2 more sources
Current Opinion in Oncology, 1994
Combinations of drugs such as methotrexate, cyclosporin A, and prednisone have reduced the incidence of graft-versus-host disease (GVHD) to 20% to 30%. However, GVDH remains a major complication (up to 90%) following allogeneic bone marrow transplantation from unrelated or mismatched donors.
openaire +2 more sources
Combinations of drugs such as methotrexate, cyclosporin A, and prednisone have reduced the incidence of graft-versus-host disease (GVHD) to 20% to 30%. However, GVDH remains a major complication (up to 90%) following allogeneic bone marrow transplantation from unrelated or mismatched donors.
openaire +2 more sources
Vulvovaginal Graft-Versus-Host Disease
Obstetrics and Gynecology Clinics of North America, 2017Vulvovaginal chronic graft-versus-host disease (cGVHD) is an underrecognized complication of stem cell transplantation. Early recognition may prevent severe sequelae. Genital involvement is associated with oral, ocular, and skin manifestations. Treatment includes topical immunosuppression, dilator use, and adjuvant topical estrogen.
Rachel I, Kornik, Alison S, Rustagi
openaire +2 more sources
2013
Graft versus host disease (GVHD) is the principal complication of allogeneic haematopoietic stem cell transplantation (HSCT). N Vascular endothelial damage and increased secretion of pro- inflammatory cytokines are involved in the pathogenesis of lung disorders.
Pulvirenti, Federica +3 more
openaire +2 more sources
Graft versus host disease (GVHD) is the principal complication of allogeneic haematopoietic stem cell transplantation (HSCT). N Vascular endothelial damage and increased secretion of pro- inflammatory cytokines are involved in the pathogenesis of lung disorders.
Pulvirenti, Federica +3 more
openaire +2 more sources
Acute Graft-Versus-Host Disease
Immunotherapy, 20111419 ISSN 1750-743X 10.2217/IMT.11.133 © 2011 Future Medicine Ltd Immunotherapy (2011) 3(12), 1419–1422 “First-line treatment of aGvHD, with methylprednisolone 2 mg/kg/day, is effective in over 50% of patients, produces durable responses but only in one out of three patients. Steroid-refractory or steroid-dependent GvHD patients are offered second-line
openaire +2 more sources
Cutaneous Graft-versus-Host Disease
Archives of Dermatology, 1998Graft-versus-host disease (GvHD) includes inflammatory and/or fibrosing manifestations that may arise at various times after transplantation of any organ containing lymphoid cells. For the dermatologist, the importance of GvHD is real and current. Indeed, because it has become easier to perform bone marrow transplantation (EMT), the indications of BMT ...
S, Aractingi, O, Chosidow
openaire +2 more sources